1. Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer

4. First-line Treatment for HR+/HER2-mBC General Tenets

5. "Non-Cytotoxic" First-Line Agents

6. Cyclin-dependent Kinases and Cell Cycle Control

7. CDK 4/6 Inhibition Is Most Effective in ER+/Luminal Breast Cancer Cells

8. Case Illustration Asymptomatic Metastatic Disease

9. First-Line Options

10. Select First-Line Therapy

11. Case Continues… Progression After First-Line Treatment

12. ESR1 Mutations in ER-Positive Metastatic Breast Cancer

13. Palbociclib Clinical Pearls (Neutropenia)

14. Palbociclib Clinical Pearls (Other AEs)

15. BELLE-2 Buparlisib + Fulvestrant

16. Emerging Strategies

17. Palbociclib + Fulvestrant

18. Abemaciclib Combinations

19. Mechanisms of Resistance

20. Summary

21. Abbreviations

22. Abbreviations (cont)